Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PolyPeptide Group AG ( (CH:PPGN) ) has provided an announcement.
PolyPeptide Group AG, a global CDMO specializing in peptide-based active pharmaceutical ingredients for pharma and biotech clients, operates six GMP-certified facilities in Europe, the U.S. and India and is listed on the SIX Swiss Exchange. The company serves a rapidly growing market for peptide therapies, notably in metabolic diseases such as GLP-1-based treatments, and supports customers from early development to commercial production.
PolyPeptide has expanded its existing syndicated credit facility to EUR 200 million, strengthening its financing structure and liquidity. The enlarged facility, coordinated by UBS and now including ING Bank alongside Danske Bank and Zürcher Kantonalbank, is intended to provide greater financial flexibility as the company pursues its strategy to double 2023 revenue by 2028 and fund major capacity-expansion projects, signaling lender confidence in its growth trajectory and capital investment plans.
The most recent analyst rating on (CH:PPGN) stock is a Hold with a CHF24.00 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.
More about PolyPeptide Group AG
PolyPeptide Group AG is a specialized contract development and manufacturing organization focused on peptide-based active pharmaceutical ingredients for pharma and biotech customers. Operating six GMP-certified sites across Europe, the U.S. and India, it serves a fast-growing market with strong exposure to metabolic disease therapies, including GLP-1 drugs.
The company supports projects from pre-clinical through commercial stages, contributing to treatments used by millions of patients worldwide. Listed on the SIX Swiss Exchange under ticker PPGN, PolyPeptide leverages its global network and long heritage dating back to 1952 to supply complex peptide APIs and related services.
Average Trading Volume: 72,986
Technical Sentiment Signal: Buy
Current Market Cap: CHF850.6M
For a thorough assessment of PPGN stock, go to TipRanks’ Stock Analysis page.